Related Experiment Videos
Relation between apolipoprotein e phenotype and the changes in lipids during tamoxifen treatment
1Department of Surgery, Omiya Medical Center, Jichi Medical School, Japan.
Endocrine Journal
|August 13, 1998
Summary
Tamoxifen treatment can cause severe hypertriglyceridemia, a condition involving high triglyceride levels. This study found that apolipoprotein E (apo E) phenotype does not significantly alter the risk of developing tamoxifen-induced lipemia.
Area of Science:
- Biochemistry
- Genetics
- Oncology
Background:
- Tamoxifen is a widely used endocrine therapy for breast cancer.
- Severe hypertriglyceridemia has been linked to tamoxifen treatment.
- Apolipoprotein E (apo E) phenotype is a known factor influencing lipoprotein metabolism.
Purpose of the Study:
- To investigate the relationship between apolipoprotein E phenotype and tamoxifen-induced changes in lipid levels.
- To clarify if specific apo E phenotypes are more susceptible to tamoxifen-induced lipemia.
Main Methods:
- Analysis of apolipoprotein E phenotypes in patients undergoing tamoxifen treatment.
- Measurement of plasma triglyceride and total cholesterol levels before and during tamoxifen therapy.
- Comparison of lipid level changes across different apo E phenotypes (E3/3, E4/3).
Main Results:
- Plasma triglyceride levels significantly increased in both apo E3/3 and apo E4/3 phenotypes during tamoxifen treatment.
- No significant difference in triglyceride levels was observed between apo E3/3 and apo E4/3 phenotypes before or during tamoxifen treatment.
- Plasma total cholesterol levels remained stable during tamoxifen treatment for both studied phenotypes.
Conclusions:
- The increase in triglyceride levels during tamoxifen treatment appears to be independent of apolipoprotein E phenotype.
- Tamoxifen-induced lipemia may occur across various apo E phenotypes.
- Further research is warranted to fully understand the mechanisms of tamoxifen-induced hypertriglyceridemia.